Oncolytics Biotech (ONCY) Operating Expenses (2009 - 2026)
Oncolytics Biotech (ONCY) posted quarterly Operating Expenses of $15.4 million for Q4 2025, up 154.96% year-over-year from $6.0 million in Q4 2024, and up 53.12% quarter-over-quarter from $10.1 million in Q3 2025.
Oncolytics Biotech (ONCY) Operating Expenses (2009 - 2026) Analysis & Trends
Oncolytics Biotech (ONCY) has reported Operating Expenses for 17 consecutive years, with $15.4 million the latest figure, recorded in Q4 2025.
- In Q4 2025, Operating Expenses rose 154.96% year-over-year to $15.4 million; the TTM figure through Dec 2025 stood at $34.5 million (up 34.77% YoY), while the FY2025 annual figure was $28.7 million, up 12.46% from the prior year.
- Operating Expenses rose to $15.4 million in Q4 2025 per ONCY's latest filing, from $10.1 million in the prior quarter.
- Across five years, Operating Expenses topped out at $15.4 million in Q4 2025 and bottomed at $2.1 million in Q1 2022.
- Historically, Operating Expenses has averaged $5.5 million across 5 years, with a median of $5.2 million in 2023.
- On a YoY basis, Operating Expenses climbed as much as 154.96% in 2025 and fell as far as 28.88% in 2025.
- Oncolytics Biotech's Operating Expenses stood at $3.0 million in 2021, then surged by 109.24% to $6.3 million in 2022, then advanced by 3.7% to $6.5 million in 2023, then slipped by 7.08% to $6.0 million in 2024, then soared by 154.96% to $15.4 million in 2025.
- Business Quant data shows ONCY's Operating Expenses at $15.4 million in Q4 2025, $10.1 million in Q3 2025, and $4.1 million in Q2 2025.
Powered by 
Peer Comparison
| # | Company | Market Cap | Enterprise Value | Gross Profit (Qtr) | Opex (Qtr) |
|---|---|---|---|---|---|
| 1 | Vertex Pharmaceuticals | 139.66 Bn | 131.80 Bn | 2.84 Bn | 2.09 Bn |
| 2 | Regeneron Pharmaceuticals | 86.52 Bn | 78.53 Bn | 3.93 Bn | 3.00 Bn |
| 3 | Argenx Se | 65.33 Bn | 60.14 Bn | 1.37 Bn | 2.89 Bn |
| 4 | Moderna | 59.76 Bn | 54.62 Bn | 52.00 Mn | 960.00 Mn |
| 5 | BeOne Medicines | 42.15 Bn | 37.05 Bn | 1.53 Bn | 1.21 Bn |
| 6 | Alnylam Pharmaceuticals | 31.84 Bn | 28.53 Bn | 992.69 Mn | 1.06 Bn |
| 7 | BioNTech SE | 28.23 Bn | 9.84 Bn | 668.28 Mn | -784.57 Mn |
| 8 | Insmed | 27.52 Bn | 26.36 Bn | 358.27 Mn | 427.03 Mn |
| 9 | Royalty Pharma | 27.29 Bn | 26.46 Bn | - | 541.02 Mn |
| 10 | Oncolytics Biotech | 98.50 Mn | 98.50 Mn | - | 9.38 Mn |
Historic Data
Download Data| Date | Value |
|---|---|
| Jun 30, 2026 | 9.38 Mn |
| Dec 31, 2025 | 15.40 Mn |
| Sep 30, 2025 | 10.06 Mn |
| Jun 30, 2025 | 4.12 Mn |
| Mar 31, 2025 | 4.88 Mn |
| Dec 31, 2024 | 6.04 Mn |
| Sep 30, 2024 | 7.26 Mn |
| Jun 30, 2024 | 5.79 Mn |
| Mar 31, 2024 | 6.48 Mn |
| Dec 31, 2023 | 6.50 Mn |
| Sep 30, 2023 | 8.24 Mn |
| Jun 30, 2023 | 5.33 Mn |
| Mar 31, 2023 | 4.98 Mn |
| Dec 31, 2022 | 6.27 Mn |
| Sep 30, 2022 | 4.65 Mn |
| Jun 30, 2022 | 2.23 Mn |
| Mar 31, 2022 | 2.05 Mn |
| Dec 31, 2021 | 3.00 Mn |
| Sep 30, 2021 | 2.28 Mn |
| Jun 30, 2021 | 2.86 Mn |